This article summarises peer-reviewed research for public education. It is not medical advice, and it is not a substitute for care from a clinician who knows your situation.
Clinical trials of psychedelics have accumulated for depression, PTSD and anxiety. Pregnant people are excluded from nearly all of them. Mental health conditions do not pause during gestation, and some people find the standard medications inadequate or worry about their risks. Anyone searching for evidence on taking mushrooms while pregnant has until recently found old case reports, drug-war messaging and little else.
Two papers published in 2026 changed that, though not in the way most people would hope. One is a systematic survey of every human study of psychedelic exposure in pregnancy. The other predicts, compound by compound, whether these drugs reach the fetus. Read together, they establish that the question has barely been studied, and that the lack of study should not be mistaken for reassurance.
How much human evidence exists: 23 studies in 55 years
Albert and Arthur (2026) published a scoping review in Therapeutic Advances in Drug Safety. They searched MEDLINE, Embase, PsycINFO, CINAHL and the Cochrane Library from each database's inception to March 2025, looking for human studies that reported maternal, obstetric, neonatal, congenital or child-development outcomes after prenatal exposure to MDMA, psilocybin, LSD, mescaline/peyote or DMT/ayahuasca. Animal studies were excluded by design.
They identified roughly 2,500 records, screened 1,510 after removing duplicates, and found 23 primary human sources, published between 1968 and 2020:
MDMA (ecstasy): 11 studies
LSD: 11 studies, most from the late 1960s and 1970s
Mescaline/peyote: one case report
Psilocybin and DMT/ayahuasca: no eligible studies at all
Psilocybin is the compound at the centre of the current research boom, and ayahuasca has a long ceremonial history. For pregnancy outcomes, neither has a single qualifying human study.
The 23 studies that do exist support few firm conclusions. Exposure was usually established by asking women what they had taken rather than by laboratory confirmation. Most of those women also used tobacco, alcohol, cannabis or other drugs, which makes it impossible to attribute any outcome to one substance. Sample sizes were small and outcome definitions varied between studies. The authors state the implication plainly: for the substances with no data, the absence of evidence must not be read as evidence of no risk.
Anxious about a past experience? A free 30-minute consultation is a confidential place to start.
What those studies found, substance by substance
MDMA
MDMA has the largest body of evidence, and it is still thin. Teratology information services and case series have reported congenital anomalies following prenatal ecstasy exposure, and a prospective cohort found motor delays in exposed infants that persisted to age two. The review is explicit that these reports cannot establish causation or quantify absolute risk: the groups were small, and the women in them frequently also smoked, drank or used other drugs.
MDMA is also pharmacologically distinct from the classic psychedelics. It acts mainly by releasing monoamines rather than by directly activating the 5-HT2A receptor, and the review states that findings from MDMA cohorts should not be generalised to LSD or psilocybin.
LSD
The LSD literature is older and almost entirely case-based: letters, case reports and observational follow-ups describing congenital malformations and ocular abnormalities in children whose mothers reported using LSD, plus two cytogenetic reports of chromosomal abnormalities in children exposed in utero. The review's conclusion is that these sources establish no consistent pattern of defects and support no risk estimate, because exposure was rarely verified, dose and timing were usually unrecorded, and the likelihood of reporting bias is high.
Psilocybin mushrooms and ayahuasca
For psilocybin and for DMT/ayahuasca, the review identified no eligible human study at all — not a weak study or a small one, but none reporting pregnancy or child outcomes after exposure. A clinician advising someone who took magic mushrooms while pregnant, whether in the first trimester or later, has no human outcome data to work from: only animal research, pharmacological modelling, and inference from other compounds.
Do these drugs reach the fetus? What the modelling predicts
A second 2026 paper, published in Molecules by a team at the Medical University of Lodz in Poland, approached the gap from pharmacology instead. They built a statistical model to predict placental transfer for 250 compounds: ketamine plus 249 serotonergic psychedelics and their analogues from the tryptamine, ergoline and phenylethylamine families.
The measure is log FM, the ratio of a drug's concentration in fetal blood to its concentration in maternal blood at equilibrium. Above −0.52, a compound is considered to cross the placenta easily; below −0.82, not to cross meaningfully; between the two, uncertain. Psilocybin scored −0.08 and psilocin −0.24, both comfortably inside the easily-crossing range. Mescaline, at −0.09, had the highest predicted transfer of any compound in the set. LSD scored −0.39. Not one of the 250 compounds fell below −0.82, although some phenylethylamines and ergolines landed in the uncertain middle band.
This is a prediction, not a measurement. The model was built from 55 drugs whose transfer ratios have actually been measured, trained on 40 of them and tested against the remaining 15. No one has measured psilocybin, LSD or DMT in human fetal blood.
Crossing the placenta is not by itself evidence of harm; many routine medications cross it. What the modelling rules out is the assumption that the placenta filters these compounds away from the fetus.
The authors also identified which molecular features drive transfer. Carbonyl, hydroxyl, nitro and phosphoryloxy groups promote it — including the phosphoryloxy group on psilocybin and the hydroxyl group on psilocin — while bulky alkyl and aryl groups, rigid polycyclic structures and halogen atoms restrict it. They note that every compound they examined would be straightforward to synthesise, which is their argument for studying this class before novel analogues reach the market.
The alternatives are also imperfect
Someone weighing psychedelics during pregnancy is usually choosing between imperfect options, not between a treatment and nothing. (For what is legally available in the United States right now, see Where Can I Get Psychedelic Therapy?)
The treatment landscape for perinatal depression has shifted. Brexanolone (Zulresso), which required a 60-hour intravenous infusion in hospital and was difficult to combine with caring for a newborn, was withdrawn from the market at the end of 2024, and the FDA withdrew its approval in April 2025. Zuranolone (Zurzuvae), approved in 2023, is an oral course taken over 14 days. Daily antidepressants such as SSRIs remain the most common approach; they carry modest and well-characterised trade-offs, including transient adjustment symptoms in some newborns and debated associations with specific birth defects, some of which may reflect the underlying depression rather than the medication.
Psychedelic-assisted therapy involves one or two supervised sessions rather than months of daily dosing, which in principle means less cumulative fetal exposure. That reasoning is not supported by any human pregnancy data for psilocybin or ayahuasca, because none exists. A single exposure to a drug whose fetal effects have never been measured is not demonstrably safer than a well-studied daily medication whose risks are small but known; the two are uncertain in different ways, and only one of them has been quantified.
Ketamine, pregnancy and breastfeeding
Ketamine sits apart from the rest. It is already used in caesarean sections, and recent trials suggest a single low dose after childbirth can reduce postpartum depression. In a small study of breastfeeding mothers, infants received less than 1% of the maternal dose, well below the level that usually prompts concern.
Where the law adds risk the science cannot measure
The human evidence on fetal risk is sparse. The legal and social consequences of using drugs during pregnancy, or of being suspected of it, are not.
As of 2023, 26 US states required healthcare providers to report suspected prenatal drug use to child protective services, up from 15 in 2016, and eight states required testing when use is suspected. Tennessee briefly permitted criminal prosecution for prenatal drug use, with theoretical sentences of up to 15 years, though most charges brought were lesser misdemeanours.
Reporting is applied unevenly. A 1990 study found that Black and white pregnant women used drugs at similar rates, yet Black mothers were reported to authorities at roughly ten times the rate. Two decades later, a California hospital that adopted universal screening still reported Black newborns at nearly five times the rate of white newborns, and adopting the protocol did not reduce the disparity. Vermont's child welfare guidance exempts cannabis-only positive results from mandatory reporting; no state carves out an exemption for psychedelics.
Families drawn into this system, who are disproportionately poor, single and of colour, can lose custody permanently. That risk is real and measurable in a way the pharmacological risk currently is not.
Cultural knowledge and harm reduction
Some communities did not wait for clinical trials, because they had generational knowledge of their own. Leticia Pizano, of the Sac and Fox and Kickapoo Tribal Nations, took part in mushroom ceremonies through her twelfth pregnancy and described forming a bond with her daughter during the ceremony that persisted after birth. Anthropologists have documented ritual psychedelic use in some Indigenous communities across generations, though how far back the practice extends and how often it involved pregnancy remain debated.
Outside those communities, groups such as Plant Parenthood and Moms on Mushrooms provide space to discuss these questions without judgement. One facilitator argues that silence is itself the larger problem, because people who cannot speak openly cannot receive education or support.
For anyone weighing this decision, the two 2026 papers support a relative ordering rather than a verdict. MDMA, the one substance with documented developmental signals in human studies, warrants more concern than the classic psychedelics. But having no data on psilocybin is not the same as having data showing it is safe. Dose, gestational timing, other substances used and the surrounding support all plausibly change the picture, and no study has measured any of them well. Where an exposure has already happened, teratology information services such as MotherToBaby exist to help clinicians and parents work through the uncertainty case by case.
What remains unknown
Whether psychedelics are safe during pregnancy is still an open question. What the 2026 papers contribute is a precise map of where the evidence is missing. A review of 55 years of human research found 23 studies, none of them on psilocybin or ayahuasca, and weak, confounded signals for everything else. Modelling indicates that these compounds reach the fetal circulation as a rule rather than as an exception.
Both papers reach the same recommendations: prospective pregnancy exposure registries, structured pharmacovigilance, clinical counselling that states the uncertainty explicitly, and harm reduction rather than punishment. Until that infrastructure exists, people will keep making consequential decisions with almost no information, and too often will encounter suspicion at the point where they need support.
Frequently asked questions
Can you take mushrooms while pregnant?
No human study has reported pregnancy or child outcomes after psilocybin exposure, so safety cannot be established either way. Modelling published in 2026 predicts that psilocybin and psilocin reach fetal blood at a substantial fraction of maternal concentrations, well within the range considered to cross the placenta easily. The accurate answer is that the risk is unmeasured, not that it has been measured and found to be low.
What if you took mushrooms before you knew you were pregnant?
Exposure during early, unrecognised pregnancy is the most common scenario described in the literature, and there is no human outcome data specific to psilocybin to draw on. A teratology information service such as MotherToBaby can review your specific circumstances with you or your clinician.
Do psychedelics pass into breast milk?
For psilocybin, LSD and ayahuasca, no human lactation data exists. Ketamine is the exception: in a small study of breastfeeding mothers, infants received less than 1% of the maternal dose.
Is MDMA riskier in pregnancy than psilocybin?
MDMA is the only one of these compounds with documented developmental signals in human studies — congenital anomaly reports and motor delays persisting to age two, both from small and confounded samples. Psilocybin shows no such signal, but it also has no human pregnancy studies at all. The comparison is therefore between a weak signal and a complete absence of evidence, not between a riskier drug and a safer one.
Want to talk it through?
Maybe you used psilocybin before you knew you were pregnant and can't stop worrying about it, or a past psychedelic experience is still with you. Either way, it can help to talk with someone who won't judge you. I'm a New York–licensed clinical psychologist and offer psychedelic integration therapy by telehealth, in English and Czech. For medical questions about your pregnancy, please talk with your OB, midwife or doctor.
References
Albert OM & Arthur A. Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling. Therapeutic Advances in Drug Safety 2026;17. doi:10.1177/20420986261436104
Sobańska AW, Sobański AM, Brzezińska E. Psychedelic Drugs Rediscovered — In Silico Study of Potential Fetal Exposure to Analogues of Psychedelic Drugs During Pregnancy. Molecules 2026;31:212. doi:10.3390/molecules31020212
Supporting sources: Singer et al., MDMA cohort follow-ups (2012–2016); McElhatton et al., Lancet 1999; Cohen et al., Pediatric Research 1968; Chasnoff et al., NEJM 1990; Roberts et al., Journal of Perinatology 2015; Guttmacher Institute state substance-use policy data; Wolfson et al. 2022 (ketamine and lactation); FDA approval of zuranolone, 2023, and withdrawal of brexanolone, 2025.
This article summarises peer-reviewed literature for public education. It is not medical advice and does not establish a clinician–patient relationship. Ingmar Gorman, PhD is a licensed psychologist offering psychedelic integration and trauma therapy by telehealth.